SCHEMBL19954

SCHEMBL19954

O=C1Cc2cc([N+](=O)[O-])ccc2N1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.71
TDP2 O95551 4/20 0.67
GAA P10253 1/20 0.56
AHR P35869 2/20 0.54
SIRT2 Q8IXJ6 1/20 0.51
CAPN9 O14815 1/20 0.50
CASP3 P42574 1/20 0.50
KIF11 P52732 1/20 0.50
PDE3B Q13370 1/20 0.49
PDE3A Q14432 1/20 0.49
CCNB2 O95067 2/20 0.47
CDK1 P06493 2/20 0.47
CCNB1 P14635 2/20 0.47
GSK3B P49841 2/20 0.47
CDK5 Q00535 2/20 0.47
CDK5R1 Q15078 2/20 0.47
CCNB3 Q8WWL7 2/20 0.47
PDK2 Q15119 1/20 0.47
CDC7 O00311 1/20 0.47
PLK4 O00444 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8198247 0.91 PGR (0.61) PGRTDP2GAAAHRSIRT2
SCHEMBL2993057 0.86 TDP2 (0.67) PGRTDP2GAAAHRCAPN9
SCHEMBL516986 0.85 KIF11 (0.67) PGRTDP2SIRT2CAPN9CASP3
SCHEMBL2616914 0.84 TDP2 (0.73) PGRTDP2CAPN9CASP3LMNA
SCHEMBL3523425 0.84 PGR (1.00) PGRTDP2KIF11PDE3BPDE3A
SCHEMBL3582558 0.84 PGR (0.56) PGRTDP2GAAAHRKIF11
SCHEMBL3579843 0.82 TDP2 (0.58) PGRTDP2GAASIRT2MAPK1
SCHEMBL2061739 0.82 KIF11 (0.56) PGRTDP2GAASIRT2CAPN9
Oxindole SCHEMBL27763978 0.81 AHR (0.70) PGRTDP2GAAAHRCASP3
SCHEMBL10080664 0.81 GAA (0.75) PGRGAALMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4291552-B1 MODULATORS OF COMPLEX I BOEHRINGER INGELHEIM INT (DE) 2025-04-09 EP claimed
CN-118754878-A Quinazoline derivative with broad-spectrum anti-tumor activity as well as preparation method and application thereof 成都安博力善生物科技有限公司 2024-10-11 CN claimed
EP-4291552-A1 MODULATORS OF COMPLEX I Boehringer Ingelheim International GmbH (DE) 2023-12-20 EP claimed
CN-116848101-A Modulators of complex I 勃林格殷格翰国际有限公司 2023-10-03 CN claimed
WO-2023027630-A9 A FLOW REACTOR, METHODS OF FABRICATION AND REACTIONS THEREOF NATIONAL UNIVERSITY OF SINGAPORE (SG) 2023-07-27 WO claimed
WO-2023027630-A2 A FLOW REACTOR, METHODS OF FABRICATION AND REACTIONS THEREOF NATIONAL UNIVERSITY OF SINGAPORE (SG) 2023-03-02 WO claimed
WO-2022171265-A1 MODULATORS OF COMPLEX I BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-08-18 WO claimed
US-20210061761-A1 MODULATORS OF COMPLEX I BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-03-04 US claimed
EP-2486115-B1 ELECTRORHEOLOGIC FLUID COMPRISING ORGANIC SUBSTANCES THAT CAN BE DOPED AND USE THEREOF FRAUNHOFER GES FORSCHUNG (DE) 2015-05-20 EP claimed
US-20070130702-A1 Dyeing process using a specific compound containing active methylene and a compound chosen from a specific aldehyde, a specific ketone, a quinone and a diiminoisoindoline or 3-aminoisoindolone derivative L'OREAL S.A. 2007-06-14 US claimed
US-7204857-B1 Dyeing method using a specific active methylene compound and a compound selected among a specific aldehyde, a specific ketone, a quinone and a di-imino-isoindoline or 3-amino-isoindolone derivative L'OREAL S.A. (FR) 2007-04-17 US claimed
EP-4736854-A2 HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS Bristol-Myers Squibb Company (US) 2026-05-06 EP disclosed
EP-4514473-B1 HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS BRISTOL MYERS SQUIBB CO (US) 2026-02-18 EP disclosed
WO-2025233641-A1 NOVEL PHOTOINDUCIBLE KINASE INHIBITORS FOR TREATING PROLIFERATIVE AND VASOPROLIFERATIVE DISEASES SEMMELWEIS EGYETEM (HU) 2025-11-13 WO disclosed
US-20250320183-A1 Modulators of BCL6 as Ligand Directed Degraders CELGENE CORPORATION (US) 2025-10-16 US disclosed
EP-0155828-A2 Process for making 2-oxindole-1-carboxamides and intermediates therefor PFIZER INC. (US) 1985-09-25 EP disclosed
EP-0153818-A2 1,3-Disubstituted 2-oxindoles as analgesic and anti-inflammatory agents PFIZER INC. (US) 1985-09-04 EP disclosed
US-RE29882-E SALT FORMATION, REARRANGEMENT, DESULFURIZATION OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1979-01-16 US disclosed
US-4118561-A ANTIBACTERIAL, SYNERGISTIC, ANTI-CANCER ACTIVITY, ANTI-FOLIC ACID ACTIVITY AMERICAN HOME PRODUCTS CORPORATION (US) 1978-10-03 US disclosed
US-3996264-A Synthesis of oxindoles from anilines and intermediates therein THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1976-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070130702-A1 Dyeing process using a specific compound containing active methylene and a compound chosen from a specific aldehyde, a specific ketone, a quinone and a diiminoisoindoline or 3-aminoisoindolone derivative KRT18, NDUFB5, NDUFB7 PGR 3793/4885TDP2 3483/4885GAA 4054/4885
US-20210061761-A1 MODULATORS OF COMPLEX I NDUFAB1, NDUFV1, NDUFB7 PGR 2585/4885TDP2 2461/4885GAA 1788/4885
US-20250320183-A1 Modulators of BCL6 as Ligand Directed Degraders BCL6, BCL6B, BCL3 PGR 1987/4885TDP2 3251/4885GAA 3440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.